Valsts: Īrija
Valoda: angļu
Klimata pārmaiņas: HPRA (Health Products Regulatory Authority)
LEVODOPA BENSERAZIDE HYDROCHLORIDE
Roche Products Limited
LEVODOPA BENSERAZIDE HYDROCHLORIDE
100/25 Milligram
Prolonged Release Capsules
Product subject to prescription which may be renewed (B)
Withdrawn
2009-10-06
IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. NO.540 OF 2007) PA0050/043/007 Case No: 2050519 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to ROCHE PRODUCTS LTD 6 FALCON WAY, SHIRE PARK, WELWYN GARDEN CITY, AL7 1TW, UNITED KINGDOM an authorisation, subject to the provisions of the said Regulations, in respect of the product MADOPAR CR 100MG/25MG PROLONGED RELEASE HARD CAPSULES The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 01/04/2009. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 04/04/2009_ _CRN 2050519_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Madopar CR 100mg/25mg Prolonged Release Hard Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains 100.0 mg levodopa and 25 mg benserazide (as benserazide hydrochloride). For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Prolonged release capsules, hard (Prolonged release Capsules) Light blue opaque body and dark green opaque cap imprinted with ‘Roche’ in red. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS In the management of Parkinsonism of idiopathic, post-encephalitic or arteriosclerotic type. In particular in patients presenting Izlasiet visu dokumentu